Abstract Details

Title Dietary Intake and the Effect on Disease Progression in People with Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-063

Objective To evaluate the association between diet and disability in people with MS.

Background People with multiple sclerosis (MS) are at increased risk of metabolic disorders. Diet is an important determinant of metabolic comorbidity in the general population and influences mechanisms implicated in MS (e.g. immune function, oxidative stress, the gut microbiota). However, studies investigating the effects of diet on disease progression is limited.

Design/Methods We conducted a cross-sectional study of people with MS who completed a 102-item food frequency questionnaire and received a neurologic exam. For each individual, we calculated the Dietary-Approaches-to-Stop-Hypertension (DASH) score, which is a composite measure of dietary quality favorably weighting an individual’s intake of fruits, vegetables, nuts and legumes, whole-grains and dairy, and unfavorably intake of sodium, sugar-sweetened beverages (SSBs) and red and processed meats. Scores ranged from 8 (poorest quality) to 40 (highest quality). We assessed the association between overall DASH scores and DASH-component foods/nutrients and disability status (via Expanded Disability Status Scale [EDSS]) categorized as mild-to-moderate (EDSS:<6) and severe (EDSS:≥6) using logistic regression models adjusting for age, sex, body-mass index (BMI), smoking and symptom duration.

Results We analyzed cross-sectional data from 135 participants (73% female, mean age: 44.6y [standard deviation; SD:13.9y], mean BMI: 24.5[SD:5.3]) who underwent dietary assessments and a neurologic exam; 30 individuals had severe disability. Overall DASH scores were not associated with disability status. With respect to individual DASH-score components, individuals in the highest quartile of SSB intake had higher risk of severe vs. mild-to-moderate disability (OR: 5.01; 95% CI: 1.03-24.37; P for trend=0.01). Other components were not associated with disability status.

Conclusions While overall diet quality was not associated with disability status in this preliminary study, we observed potential association between SSBs and higher disability status in MS patients. Longitudinal studies are needed to evaluate if diet impacts future disability.

Authors/Disclosures
Elisa Meier-Gerdingh, MD (Bergmannsheil Bochum) PRESENTER	No disclosure on file
Kathryn Fitzgerald, PhD (Johns Hopkins University)	Dr. Fitzgerald has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Setpoint Medical. The institution of Dr. Fitzgerald has received research support from NIH. The institution of Dr. Fitzgerald has received research support from National MS Society.
Ralf Gold, MD (Neurologische Universitaetsklinik)	Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen . Dr. Gold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer Vital. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharamaceuticals. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SAGE Publishers. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Novartis. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Biogen. The institution of Dr. Gold has received research support from Novartis. The institution of Dr. Gold has received research support from Biogen.
Kerstin Hellwig (St. Josef Hospital Bochum)	Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mylan . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche . The institution of Kerstin Hellwig has received research support from Roche . The institution of Kerstin Hellwig has received research support from Merck . The institution of Kerstin Hellwig has received research support from Biogen. The institution of Kerstin Hellwig has received research support from Genzyme . The institution of Kerstin Hellwig has received research support from Novartis . The institution of Kerstin Hellwig has received research support from BMS .

��ɫ��

��ɫ��